14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $34.63 $65.60 Friday, 3rd May 2024 JANX stock ended at $64.78. This is 3.76% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 10.61% from a day low at $59.31 to a day high of $65.60.
90 days $7.79 $65.60
52 weeks $5.65 $65.60

Historical Janux Therapeutics, Inc. prices

Date Open High Low Close Volume
May 03, 2024 $63.98 $65.60 $59.31 $64.78 1 038 725
May 02, 2024 $59.94 $64.71 $56.41 $62.43 1 108 984
May 01, 2024 $57.00 $60.05 $55.55 $58.19 905 280
Apr 30, 2024 $54.88 $57.11 $53.78 $57.00 652 969
Apr 29, 2024 $47.85 $60.84 $47.58 $56.08 1 531 196
Apr 26, 2024 $47.08 $48.23 $46.61 $47.39 571 989
Apr 25, 2024 $48.30 $48.30 $45.68 $47.10 550 099
Apr 24, 2024 $49.95 $50.06 $46.55 $48.21 574 544
Apr 23, 2024 $49.31 $50.42 $48.28 $49.78 706 616
Apr 22, 2024 $49.66 $49.95 $44.71 $48.88 1 116 713
Apr 19, 2024 $48.14 $49.13 $46.45 $48.69 663 085
Apr 18, 2024 $47.87 $49.00 $47.32 $48.85 392 131
Apr 17, 2024 $50.00 $51.21 $47.28 $47.96 614 162
Apr 16, 2024 $52.10 $52.33 $50.02 $50.55 529 276
Apr 15, 2024 $51.05 $54.59 $50.43 $51.86 1 035 953
Apr 12, 2024 $49.94 $54.76 $49.53 $52.65 1 519 620
Apr 11, 2024 $47.06 $56.26 $47.01 $50.00 2 662 242
Apr 10, 2024 $39.00 $49.00 $38.08 $44.62 3 284 138
Apr 09, 2024 $38.60 $40.50 $38.43 $40.03 702 934
Apr 08, 2024 $35.46 $39.05 $35.03 $38.63 296 065
Apr 05, 2024 $35.16 $35.68 $34.63 $35.12 277 715
Apr 04, 2024 $36.95 $37.77 $35.32 $35.40 304 375
Apr 03, 2024 $36.33 $36.45 $35.11 $36.34 283 693
Apr 02, 2024 $36.23 $36.60 $34.76 $35.87 492 598
Apr 01, 2024 $37.62 $38.10 $35.33 $37.69 286 736
Click to get the best stock tips daily for free!

About Janux Therapeutics, Inc.

Janux Therapeutics. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. Janux Therapeutics, Inc. is also developing a ... JANX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT